Search

Objective: To check the Bacterial Co-infections and Susceptibility patterns among admitted COVID-19 patients during 3rd wave of pandemic. Study Design: Descriptive Cross Sectional study. Setting: Department of Microbiology, Combined Military Hospital Lahore Pakistan. Period: May 2021 to August 2021. Material & Methods: Six hundred and twelve COVID-19 positive patients having positive bacterial cultures were processed, Antibiotic susceptibility testing was done by Kirby-Bauer diffusion technique, all antibiotics were reported using breakpoints recommended in clinical and laboratory standards institute (CLSI 2021). Results: Out of 612 patients, 348 (56.9%) were male and 264 (43.2%) were female. Mean age of the patients was 57.2 ± 14.4 years with a range of 22 to 89 years. Bacterial coinfection was present in 70.4% of the patients. Gram negative bacteria (94.4%) were more prevalent in COVID-19 patients as compared to gram positive isolates (5.6%). Antibiotic sensitivity pattern of Staphylococcus aureus showed a high resistance against penicillin, ampicillin, tetracycline and doxycycline. Conclusion: Our study reported a high prevalence of bacterial coinfections in COVID-19 patients infected during the third wave of pandemic. A high percentage of gram negative species were identified in our study population, this could be due to the suppression in the immunity of individuals due to severity of COVID-19 infection and already present Antimicrobial resistance.

Objective: To compare the Minimal Inhibitory Concentration (MIC) of Azithromycin in Extremely Drug Resistant (XDR) Salmonella enterica serovar Typhi (S. Typhi), Pre-COVID and after one year of COVID-19 pandemic. Methodology: This cross-sectional study was conducted in the Department of Microbiology, Combined Military Hospital, Lahore, Pakistan, from May 2021 to April 2022. All XDR S. Typhi isolated during the study period were included and tested. Kirby –Bauer Disk Diffusion method was used for antibiotic susceptibility, and Azithromycin MIC was determined by the E-strip method. The latest Clinical & Laboratory Standards Institute (CLSI) breakpoints for Azithromycin susceptibility testing were used. Results: A total of 384 XDR S. Typhi were included in the study. MICs of these isolates were in the ranges of 2-16ug/mL, and all were sensitive to Azithromycin as per CLSI standards. These were further compared with MICs of the pre-covid isolates. The MICs of the isolates were relatively higher as compared to pre-COVID MICs. Conclusion: The potential Azithromycin resistance in XDR Salmonella Typhi is knocking at the door. Sensitivity patterns should be reported with MICs values, and if possible higher values should be screened for the presence of any potential resistance genes. Antibiotic stewardship should be strictly implemented.

Objective: To describe aetiology and antibiotic susceptibility pattern of bacterial pathogens in respiratory specimens of covid-19 patients on respiratory support in tertiary care hospital of Lahore. Study Design: Descriptive study. Setting: Microbiology Department, CMH, Lahore. Period: May 2021 to October 2021. Material & Methods: A total 107 isolates from 145 patients who were COVID-19 positive and on respiratory support were included in the study. Bacterial isolates were isolated from clinical samples according to standard protocol of culturing and incubation. Antibiotic sensitivity, carbapenamase detection was done according to CLSI 2021. Molecular identification of carbapenem resistant genes blaIMP and blaVIM was determined by PCR. Results: A total of 107 bacterial isolates were isolated from clinical specimens. A. baumannii was the most common isolated organism. Colistin and aminoglycosides were found to be the most effective antibiotics. Among carbapenem resistant isolates 89.5% were MHT positive and among these 59 (86.8%) were MBL positive. Among MBL positive isolates, 5.61% and 29.91% were positive for blaIMP and blaVIM respectively. Conclusion: Patients admitted for COVID-19 treatment are at higher risk of acquisition of secondary bacterial infections and antibiotic resistance among such pathogens is at alarming.

The presence of large anharmonicity and lattice softness in low dimensional metal halide, RbPb2Br5 nanoplates, trigger strong electron–phonon coupling and consequently highly Stokes shifted broadband emission originates from self-trapped excitons.

Cancer represents one of the world's biggest hazardous diseases. p53 is the uttermost researched tumour suppressor protein. It is commonly considered the "guardian of the genome," performing a critical function in genetic stability maintenance through controlling the cell cycle, programmed cell death, DNA repair, aging, and angiogenesis. The abnormalities in p53 lead to genetic instability and plays a significant role in carcinogenesis. The role of p53 in tumour suppression is emphasized in addition by the observation that primary silencing with this protein occurred in more than 50% of cancers. MDM2, p53, and the p53-MDM2 connections are well-known targets for the prevention and treatment of cancer. Moreover, in tumors with wild-type p53, their efficacy is decreased due to MDM2 enlargement or by the gradual decrease of MDM2 blocker ARF. As a result, improving p53 activity in cancerous cells provides a promising anticancer strategy. Various techniques are now being investigated, and addressing the p53-MDM2 interaction had also evolved as a potentially feasible strategy for contending with tumors. Both p53 and MDM2, interact via an autoregulation response signal: p53 activity induces MDM2 transcription, which in response interacts with p53's N-terminal transactivation domain, inhibiting its transcriptional activity. This article provides information on the current scenario of anti-tumor activities, with a particular emphasis on structure-activity relationship characteristics (SAR) against the p53-MDM2 to treat cancer. The primary purpose of this review is to cover recent advancements in the creation and testing of anticancer drugs that target the p53-MDM2 structure. This review contains different heterocyclic moieties which show significant results toward cancer. A mechanistic route is shown here, demonstrating both normal and malignant conditions via several stressed factors. Several compounds entered clinical trials as p53-MDM2 inhibitors for the treatment of cancer.